Exelixis

Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.

Originally published Dec. 23.
EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

Around the Regions

Premium

Gaithersburg West Master Plan, Ben Franklin Technology Partners, University of Houston Institute of Biomedical Research, Connecticut Economic Development Consolidations, South San Francisco Life Sciences Career Fair, New York City Biotechnology Tax Credit

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.